Sangamo and Astellas Unite for Neurological Treatment Advances
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), renowned in the field of genomic medicine, has announced an exciting new collaboration with Astellas Pharma Inc. This partnership focuses on leveraging Sangamo’s novel neurotropic adeno-associated virus (AAV) capsid technology, known as STAC-BBB. This advanced platform is designed to breach the barriers of the human blood-brain barrier, enabling effective delivery of targeted gene therapies aimed at treating serious neurological diseases.
Details of the Licensing Agreement
The newly formed license agreement allows Astellas to exclusively utilize the STAC-BBB capsid for a designated treatment target. Furthermore, they have the potential to add up to four additional treatment targets upon payment of extra licensing fees. This strategic alliance paves the way for delivering genomic medicines through intravenous methods, addressing neurological disorders that currently lack sufficient treatment options.
Leadership Perspectives
Sandy Macrae, the CEO of Sangamo, expressed his excitement about the capabilities of STAC-BBB. He emphasized the challenges faced in delivering therapies to the central nervous system and the immense potential of their AAV capsid technology to help overcome these difficulties. Macrae stated, 'This agreement underscores the continued industry interest in our STAC-BBB capsid and reinforces our ongoing commitment to partnering with collaborators who understand its unique potential.'
Adam Pearson, Astellas' Chief Strategy Officer, also highlighted the complexities involved in delivering treatments to the brain and central nervous system. He elaborated, 'Technologies such as Sangamo’s STAC-BBB capsid could prove critical in helping us deliver effective transformational treatments to patients suffering from serious genetic neurological conditions.'
Financial Aspects of the Collaboration
Under this agreement, Sangamo is set to receive an upfront licensing fee of $20 million from Astellas. They could potentially earn an additional $1.3 billion through licensed target fees and achievement milestones related to the five targeted neurological disorders. This financial structure showcases the significant promise that both parties see in this innovative approach to genomic therapy.
The Vision for the Future
Sangamo Therapeutics has a clear mission to transform the lives of patients affected by serious neurological diseases through groundbreaking scientific advances. Their use of zinc finger epigenetic regulators is aimed at addressing complex neurological disorders effectively. In addition, their capsid discovery platform promises to extend capabilities beyond existing treatment methods currently available in intrathecal delivery.
About Sangamo Therapeutics
Sangamo is at the forefront of genomic medicine, focusing on creating transformative therapies for patients with pressing medical needs. With a robust pipeline that includes various partnered programs, Sangamo is actively seeking additional collaborations to extend its impact in genomic therapy development.
About Astellas
Astellas is a leading global life sciences company, dedicated to translating innovative science into value-driven treatments for patients. The company's therapeutic areas of focus encompass a variety of conditions, such as oncology, immunology, and ophthalmology, demonstrating their commitment to high unmet medical needs.
Frequently Asked Questions
What is the purpose of the collaboration between Sangamo and Astellas?
The collaboration aims to utilize Sangamo's STAC-BBB technology to develop gene therapies for neurological diseases, enhancing treatment delivery to the brain.
How much is Sangamo set to receive from this agreement?
Sangamo will receive an upfront licensing fee of $20 million and has the potential to earn up to $1.3 billion in additional fees and milestone payments.
What are the main challenges in delivering therapies to the central nervous system?
Key challenges include breaching the blood-brain barrier and ensuring effective transduction into neuronal cells.
What does STAC-BBB stand for?
STAC-BBB refers to Sangamo’s proprietary neurotropic AAV capsid designed specifically for enhanced delivery of gene therapies across the blood-brain barrier.
How does this partnership benefit patients?
This partnership aims to develop innovative therapies addressing serious neurological conditions that currently have limited or no effective treatments.
